A study published in The Lancet Respiratory Medicine found that a short-duration antibiotic course for ventilator-associated pneumonia (VAP) was just as effective as usual care with respect to mortality and pneumonia recurrences. The REGARD-VAP trial included 461 adults from 6 hospitals in Nepal, Singapore, and Thailand. Participants were randomly assigned to either a short-duration antibiotic cohort or usual care. The study found that the short-duration group had similar outcomes to the usual care group, with a decreased overall mean antibiotic treatment length and a lower proportion of patients experiencing antibiotic side effects. The researchers concluded that clinical response should be used to individualize antibiotic treatment duration for VAP.
Source link